Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceleration and expansion of its clinical therapeutic strategy. The company is set to embark on a new Phase I/IIa basket trial, encompassing five distinct cancer indications, utilizing its groundbreaking uPAR theranostic platform approach.

The forthcoming trial is designed to investigate Curasight's pioneering theranostic methodology, which integrates both diagnosis (uTRACE®) and therapy (uTREAT®). Scheduled to commence in the beginning of 2025, the trial aims to evaluate the efficacy of Curasight's platforms across brain cancer (Glioblastoma), neuroendocrine tumors (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer.

"We believe the theranostic approach using radiopharmaceuticals to both diagnose and treat certain types of cancer has the potential to provide important new solutions to clinicians and patients," remarked Curasight's CEO, Ulrich Krasilnikoff. "By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025."

The decision to expand its clinical endeavors comes as part of Curasight's commitment to establishing itself as a front-runner in the field of theranostics within radiopharmaceuticals and diagnostics. Leveraging the versatility of its uPAR-targeted approach, which is expressed in the majority of solid cancers, Curasight aims to provide more targeted, gentler, and efficient treatment options for cancer patients.

To facilitate the acceleration of clinical activities, Curasight intends to bolster its capital structure through a rights issue scheduled for the first quarter of 2024. Details of the rights issue will be disclosed in a subsequent press release.

The announcement follows Curasight's ongoing Phase II trial investigating uTRACE in prostate cancer, conducted in partnership with Curium Inc., with interim data expected in Q3 2024. Under the terms of the collaboration, Curasight assumes responsibility for development until regulatory approval, with Curium managing manufacturing and commercialization. Curasight stands to gain up to mUSD 70 in development and commercial milestones, as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

Curasight's bold strides toward advancing its therapeutic strategy underscore its dedication to pioneering innovative solutions that have the potential to redefine cancer treatment paradigms.